SCHEMBL4954832

SCHEMBL4954832

CCN(C(=O)[C@H](CC(C)C)NN1CCNCC1)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
GLA P06280 1/20 0.41
TSHR P16473 1/20 0.41
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
KDM4E B2RXH2 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CTSL P07711 5/20 0.39
CTSB P07858 5/20 0.39
CTSS P25774 5/20 0.39
OPRD1 P41143 3/20 0.38
OPRM1 P35372 2/20 0.38
GAA P10253 1/20 0.37
GPR88 Q9GZN0 1/20 0.37
CTSK P43235 4/20 0.36
OPRK1 P41145 1/20 0.36
TP53 P04637 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4867352 0.86 CTSS (0.42) ALDH1A1GLATSHRMEN1KMT2A
SCHEMBL4866152 0.81 ALDH1A1 (0.41) ALDH1A1GLATSHRMEN1KMT2A
SCHEMBL14938327 0.72 MEN1 (0.50) ALDH1A1GLATSHRMEN1KMT2A
SCHEMBL4957420 0.71 ALDH1A1 (0.47) ALDH1A1GLATSHRMEN1KMT2A
SCHEMBL2170762 0.71 MEN1 (0.43) ALDH1A1GLATSHRMEN1KMT2A
SCHEMBL4866531 0.70 GAA (0.48) CTSLCTSBCTSSGAACTSK
SCHEMBL4558907 0.70 ALDH1A1 (0.50) ALDH1A1GLATSHRMEN1KMT2A
SCHEMBL4558670 0.70 ALDH1A1 (0.50) ALDH1A1GLATSHRMEN1KMT2A
SCHEMBL3965574 0.69 GPR88 (0.46) ALDH1A1GLATSHRCTSLCTSB
SCHEMBL18765958 0.69 ALDH1A1 (0.66) ALDH1A1GLATSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140256743-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK FROSST CANADA LTD. (CA) 2014-09-11 US disclosed
US-8772336-B2 Cathepsin cysteine protease inhibitors MERCK FROSST CANADA LTD. (CA) 2014-07-08 US disclosed
US-20130035312-A1 CATHEPSIN CYSTEINE PROTEASE INHIBIORS AXYS PHARMACEUTICALS, INC. (US) 2013-02-07 US disclosed
US-8318748-B2 Cathepsin cysteine protease inhibitors Merck, Sharp & Dohme Corp. (US) 2012-11-27 US disclosed
US-20080188529-A1 N1-(cyanomethyl)-N2-(2,2,2-trifluoro-1-phenylethyl)-L-leucinamide; antiarthritic agent; osteoporosis and other bone loss disorders MERCK CANADA INC. (CA) 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130035312-A1 CATHEPSIN CYSTEINE PROTEASE INHIBIORS CTSB, CTSS, CTSZ ALDH1A1 3969/4885GLA 98/4885TSHR 2897/4885
US-20140256743-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ ALDH1A1 4582/4885GLA 137/4885TSHR 3675/4885
US-20080188529-A1 N1-(cyanomethyl)-N2-(2,2,2-trifluoro-1-phenylethyl)-L-leucinamide; antiarthritic agent; osteoporosis and other bone loss disorders CTSE, CTSL, CTSK ALDH1A1 4285/4885GLA 204/4885TSHR 3760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.